Tumor Biology

, Volume 34, Issue 6, pp 3437–3441 | Cite as

Association between vitamin D receptor gene Cdx2 polymorphism and breast cancer susceptibility

  • Zhu-Chao Zhou
  • Jie Wang
  • Zi-Hao Cai
  • Qun-hua Zhang
  • Zhen-Xin Cai
  • Jian-Hua Wu
Research Article


Vitamin D receptor (VDR) gene polymorphisms have been reported to influence susceptibility to breast cancer. However, published findings on the association between VDR Cdx2 polymorphism and breast cancer susceptibility are conflicting. To get a precise estimation of the association between VDR Cdx2 polymorphism and breast cancer susceptibility, we conducted a meta-analysis of four case–control studies with a total of 8,880 subjects (3,841 cases and 5,039 controls). The results showed that VDR Cdx2 polymorphism was not associated with risk of breast cancer (A versus G: OR = 0.96, 95 % CI 0.84–1.09; AA versus GG: OR = 0.97, 95 % CI 0.64–1.45; AA/GA versus GG: OR = 0.94, 95 % CI 0.80–1.10; AA versus GG/GA: OR = 0.99, 95 % CI 0.65–1.51). Subgroup analysis in Caucasians also showed that VDR Cdx2 polymorphism was not associated with risk of breast cancer in Caucasians. However, there was a significant association in Africans (A versus G: OR = 0.75, 95 % CI 0.60–0.94; AA versus GG: OR = 0.53, 95 % CI 0.29–0.99; AA/GA versus GG: OR = 0.75, 95 % CI 0.57–0.97). Therefore, the association between VDR Cdx2 polymorphism and breast cancer susceptibility is only found in Africans. More studies are needed to further assess the association in Asians or Africans.


Vitamin D receptor Breast cancer Association Polymorphism 


Conflicts of interest



  1. 1.
    Warner E. Clinical practice. Breast-cancer screening N Engl J Med. 2011;365:1025–32.Google Scholar
  2. 2.
    Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst. 2010;102:680–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst. 2010;102:1224–37.PubMedCrossRefGoogle Scholar
  4. 4.
    Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol. 2010;7:251–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299:2423–36.PubMedCrossRefGoogle Scholar
  6. 6.
    Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7:684–700.PubMedCrossRefGoogle Scholar
  7. 7.
    Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov. 2010;9:941–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Bertone-Johnson ER. Vitamin D and breast cancer. Ann Epidemiol. 2009;19:462–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29:3511–36.PubMedGoogle Scholar
  10. 10.
    Tang C, Chen N, Wu M, Yuan H, Du Y. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;117:391–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Abbas S, Nieters A, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, et al. Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Res. 2008;10:R31.PubMedCrossRefGoogle Scholar
  12. 12.
    Anderson LN, Cotterchio M, Cole DE, Knight JA. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among caucasian women in ontario. Cancer Epidemiol Biomarkers Prev. 2011;20:1708–17.PubMedCrossRefGoogle Scholar
  13. 13.
    Yao S, Zirpoli G, Bovbjerg DH, Jandorf L, Hong CC, Zhao H, et al. Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African–American women: a case–control study. Breast Cancer Res. 2012;14:R58.PubMedCrossRefGoogle Scholar
  14. 14.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  16. 16.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  17. 17.
    Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:827–38.PubMedCrossRefGoogle Scholar
  19. 19.
    Mondul AM, Weinstein SJ, Horst RL, Purdue M, Albanes D. Serum vitamin D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial. Cancer Epidemiol Biomarkers Prev. 2012;21:1222–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Chen L. Davey Smith G, Evans DM, Cox A, Lawlor DA, Donovan J, Yuan W, Day IN, Martin RM, Lane A, Rodriguez S, Davis M, Zuccolo L, Collin SM, Hamdy F, Neal D, Lewis SJ: Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev. 2009;18:2874–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Touvier M, Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2011;20:1003–16.PubMedCrossRefGoogle Scholar
  22. 22.
    Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA. 2012;308:1898–905.PubMedCrossRefGoogle Scholar
  23. 23.
    Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, et al. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer. 2012;130:405–18.PubMedCrossRefGoogle Scholar
  24. 24.
    Jiao Z, Li D. Lack of association between MHTFR Glu429Ala polymorphism and breast cancer susceptibility: a systematic review and meta-analysis of 29 research studies. Tumour Biol. 2013;34:1225–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Dai G, Guo Z, Yang X, Yu B, Li L. Association of 8q24 rs13281615A > G polymorphism with breast cancer risk: evidence from 40,762 cases and 50,380 controls. Mol Biol Rep. 2013;40:4065–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Liu JJ, Liu JL, Zhang X, Xie L, Zeng J. A meta-analysis of the association of glutathione S-transferase P1 gene polymorphism with the susceptibility of breast cancer. Mol Biol Rep. 2013;40:3203–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Yao F, Fang Y, Chen B, Jin F, Wang S. Association between the NBS1 Glu185Gln polymorphism and breast cancer risk: a meta-analysis. Tumour Biol. 2013;34:1255–62.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Zhu-Chao Zhou
    • 1
  • Jie Wang
    • 1
  • Zi-Hao Cai
    • 1
  • Qun-hua Zhang
    • 1
  • Zhen-Xin Cai
    • 1
  • Jian-Hua Wu
    • 1
  1. 1.Department of General Surgery, Huashan HospitalFudan UniversityShanghaiChina

Personalised recommendations